Qiagen (NYSE:QGEN) Updates FY 2024 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.160- for the period, compared to the consensus earnings per share estimate of 2.120. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of 2.160.

Qiagen Stock Performance

QGEN traded down $0.09 during trading on Friday, reaching $45.42. 847,455 shares of the company were exchanged, compared to its average volume of 1,245,056. The stock has a market cap of $10.36 billion, a P/E ratio of 30.46, a PEG ratio of 3.19 and a beta of 0.40. The firm has a 50 day moving average of $42.85 and a 200 day moving average of $43.04. The company has a current ratio of 1.77, a quick ratio of 1.45 and a debt-to-equity ratio of 0.27. Qiagen has a 52 week low of $34.74 and a 52 week high of $46.55.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. The firm had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The firm’s revenue was down .2% on a year-over-year basis. During the same period in the prior year, the business earned $0.53 EPS. On average, sell-side analysts forecast that Qiagen will post 2.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on QGEN. Wolfe Research upgraded Qiagen from a peer perform rating to an outperform rating and set a $50.00 price objective for the company in a report on Thursday, June 27th. Stifel Nicolaus cut their price objective on Qiagen from $55.00 to $45.00 and set a hold rating for the company in a report on Wednesday, May 1st. JPMorgan Chase & Co. upped their price objective on Qiagen from $52.00 to $54.00 and gave the company an overweight rating in a report on Tuesday, June 18th. Finally, Robert W. Baird upped their price objective on Qiagen from $49.00 to $52.00 and gave the company an outperform rating in a report on Friday, August 2nd. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average price target of $51.10.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.